A group of computer science and engineering students at the Carlos III Universidad in Madrid used natural language processing techniques to translate social-media and forum posts into adverse drug reaction data.
At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
A recent analysis found that most websites touting personal cancer medicine failed to provide risk data, while an insurer and a health system team up to develop best practices to improve the "how" of genetic testing.
A new survey from Cegedim Relationship Management claims that digital tools are being underutilized and represent an opportunity to meet the demands of HCPs.
FDA approves the first biosimilar, judge rules that FDA panel members had conflicts of interest, and a new venture will evaluate the effectiveness of digital health technologies.
Millennials and baby boomers have a lot of common: a desire for technology that supports health priorities.
Search queries for common diseases on the websites for the CDC and WebMD, among others, are being sent to third-party corporations.
FDA approves Novartis's Farydak for multiple myeloma; Shire acquires rare-disease drug for $70 million; FTC fines melanoma app marketers.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- Lawmakers propose allowing pharma companies to share some off-label information
- US pharma market value projected to be $550 billion in five years
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Apple's ResearchKit: Five Guidelines for Pharma